A BILL 
To amend title XI of the Social Security Act to provide 
for drug manufacturer price transparency. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Stopping the Pharma-
4
ceutical Industry from Keeping drugs Expensive Act’’ or 
5
the ‘‘SPIKE Act’’. 
6
01:38 Jul 27, 2021
H4418
2 
•HR 4418 IH
SEC. 2. DRUG MANUFACTURER PRICE TRANSPARENCY. 
1
Title XI of the Social Security Act (42 U.S.C. 1301 
2
et seq.) is amended by inserting after section 1128K the 
3
following new section: 
4
‘‘SEC. 
1128L. 
DRUG 
MANUFACTURER 
PRICE 
TRANS-
5
PARENCY. 
6
‘‘(a) IN GENERAL.—With respect to each year, begin-
7
ning with 2023, the Secretary shall, at least once during 
8
such year, determine if there is a triggered SPIKE in-
9
crease (in accordance with subsection (b)) with respect to 
10
an applicable drug (as defined in subsection (f)(1)). If the 
11
Secretary determines, with respect to a year, there is such 
12
an increase with respect to an applicable drug, the manu-
13
facturer of the applicable drug shall submit to the Sec-
14
retary the justification described in subsection (c), subject 
15
to subsection (b)(3), for each such triggered SPIKE in-
16
crease in accordance with the timing described in sub-
17
section (d). 
18
‘‘(b) TRIGGERED SPIKE INCREASE.— 
19
‘‘(1) IN
GENERAL.—A triggered SPIKE in-
20
crease occurs, with respect to an applicable drug and 
21
year (beginning with 2023), in any of the following 
22
cases: 
23
‘‘(A) If there is a 10 percent (or $10,000) 
24
increase with respect to the wholesale acquisi-
25
tion cost (or alternative cost measure specified 
26
01:38 Jul 27, 2021
H4418
3 
•HR 4418 IH
by the Secretary under paragraph (2)) of such 
1
drug during any 12-month period beginning 
2
and ending within the lookback period that is 
3
the 5-year period preceding 2023 or 2024, re-
4
spectively. 
5
‘‘(B) If there is a 25 percent (or $25,000) 
6
increase with respect to the wholesale acquisi-
7
tion cost (or such alternative cost measure) of 
8
such drug during any 36-month period begin-
9
ning and ending within such respective lookback 
10
period. 
11
‘‘(C) In the case of such a drug that is 
12
first covered under title XVIII with respect to 
13
such year, if the estimated cost or spending 
14
under such title per individual or per user of 
15
such drug (as estimated by the Secretary) for 
16
such year (or per course of treatment, as de-
17
fined by the Secretary) is at least $26,000. 
18
‘‘(2) ALTERNATIVE
TO
WAC.—The Secretary 
19
may, for purposes of making determinations under 
20
paragraph (1), in addition to using the wholesale ac-
21
quisition cost for an applicable drug, use alternative 
22
cost measures of such drug. 
23
‘‘(3) EXCEPTION.—A justification under sub-
24
section (c) shall not be required for a triggered 
25
01:38 Jul 27, 2021
H4418
4 
•HR 4418 IH
SPIKE increase described in paragraph (1) of an 
1
applicable drug of a manufacturer if there is any 
2
portion of the lookback period described in the re-
3
spective subparagraph of such paragraph for such 
4
increase that is included within the lookback period 
5
for another triggered SPIKE increase (or combina-
6
tion of such increases) for which a justification is 
7
made under this section for such drug by such man-
8
ufacturer. 
9
‘‘(4) UNIT DETERMINATION.—For purposes of 
10
determining the wholesale acquisition cost in car-
11
rying out this section, the Secretary shall determine 
12
a unit (such as a unit size) to apply. 
13
‘‘(5) PUBLIC POSTING.—Beginning with respect 
14
to 2023, the Secretary shall publicly post on the 
15
Internet website of the Department of Health and 
16
Human Services— 
17
‘‘(A) 
alternative 
percentages, 
dollar 
18
amounts, and lookback periods that, if applied 
19
under paragraph (1), would be projected to in-
20
crease the number of applicable drugs for which 
21
a triggered SPIKE increase would occur for 
22
such year; and 
23
‘‘(B) the number of applicable drugs for 
24
which a triggered SPIKE increase would occur 
25
01:38 Jul 27, 2021
H4418
5 
•HR 4418 IH
for such year of such an alternative percentage, 
1
dollar amount, or period were applied for such 
2
year. 
3
‘‘(c) JUSTIFICATION DESCRIBED.— 
4
‘‘(1) IN GENERAL.—The justification described 
5
in this subsection, with respect to a triggered 
6
SPIKE increase described in subsection (b)(1) of an 
7
applicable drug of a manufacturer, is— 
8
‘‘(A) all of the information described in 
9
paragraph (2); 
10
‘‘(B) all of the information and supporting 
11
documentation described in paragraph (3), as 
12
applicable to the increase and drug; and 
13
‘‘(C) a certification described in paragraph 
14
(4). 
15
‘‘(2) REQUIRED INFORMATION.—For purposes 
16
of paragraph (1), the information described in this 
17
paragraph is the following: 
18
‘‘(A) The individual factors that have con-
19
tributed to the increase in the wholesale acqui-
20
sition cost. 
21
‘‘(B) An explanation of the role of each 
22
factor in contributing to such increase. 
23
‘‘(3) INFORMATION AS APPLICABLE.—For pur-
24
poses of paragraph (1), the information and sup-
25
01:38 Jul 27, 2021
H4418
6 
•HR 4418 IH
porting documentation described in this paragraph is 
1
the following: 
2
‘‘(A) Total expenditures of the manufac-
3
turer on— 
4
‘‘(i) materials and manufacturing for 
5
such drug; 
6
‘‘(ii) acquiring patents and licensing 
7
for each drug of the manufacturer; and 
8
‘‘(iii) costs to purchase or acquire the 
9
drug from another company, if applicable. 
10
‘‘(B) The percentage of total expenditures 
11
of the manufacturer on research and develop-
12
ment for such drug that was derived from Fed-
13
eral funds. 
14
‘‘(C) The total expenditures of the manu-
15
facturer on research and development for such 
16
drug. 
17
‘‘(D) The total revenue and net profit gen-
18
erated from the applicable drug for each cal-
19
endar year since drug approval. 
20
‘‘(E) The total costs associated with mar-
21
keting and advertising for the applicable drug. 
22
‘‘(F) Additional information specific to the 
23
manufacturer of the applicable drug, such as— 
24
01:38 Jul 27, 2021
H4418
7 
•HR 4418 IH
‘‘(i) the total revenue and net profit of 
1
the manufacturer for the period of such in-
2
crease, as determined by the Secretary; 
3
‘‘(ii) metrics used to determine execu-
4
tive compensation; 
5
‘‘(iii) total expenditures on— 
6
‘‘(I) drug research and develop-
7
ment; or 
8
‘‘(II) clinical trials on drugs that 
9
failed to receive approval by the Food 
10
and Drug Administration; and 
11
‘‘(iv) any additional information re-
12
lated to drug pricing decisions of the man-
13
ufacturer. 
14
‘‘(G) Any other relevant information and 
15
supporting documentation necessary to justify 
16
the triggering SPIKE increase. 
17
‘‘(H) Any other relevant information and 
18
supporting documentation, as specified by the 
19
Secretary. 
20
‘‘(4) CERTIFICATION.—For purposes of para-
21
graph (1), the certification described in this para-
22
graph is a certification, that all such information 
23
and documentation is accurate and complete, by one 
24
of the following: 
25
01:38 Jul 27, 2021
H4418
8 
•HR 4418 IH
‘‘(A) The chief executive officer of the 
1
manufacturer. 
2
‘‘(B) The chief financial officer of the 
3
manufacturer. 
4
‘‘(C) An individual who has delegated au-
5
thority to sign for, and who reports directly to, 
6
such chief executive officer or chief financial of-
7
ficer. 
8
‘‘(d) TIMING.— 
9
‘‘(1) NOTIFICATION.—Not later than 60 days 
10
after the date on which the Secretary makes the de-
11
termination that there is a triggering SPIKE in-
12
crease with respect to an applicable drug, the Sec-
13
retary shall notify the manufacturer of the applica-
14
ble drug of such determination. 
15
‘‘(2) SUBMISSION
OF
JUSTIFICATION.—Not 
16
later than 90 days after the date on which a manu-
17
facturer receives a notification under paragraph (1), 
18
subject to subsection (b)(3), the manufacturer shall 
19
submit to the Secretary the justification required 
20
under subsection (a), including a summary of such 
21
justification, in a form and manner specified by the 
22
Secretary. In specifying such form, with respect to 
23
the summary required under the previous sentence, 
24
the Secretary shall provide that such summary shall 
25
01:38 Jul 27, 2021
H4418
9 
•HR 4418 IH
be in an easily understandable format, as specified 
1
by the Secretary, and shall permit the manufacturer 
2
to exclude proprietary information from such sum-
3
mary. 
4
‘‘(3) POSTING
ON
INTERNET
WEBSITE.—Not 
5
later than 30 days after receiving the complete jus-
6
tification under paragraph (2), the Secretary shall 
7
post on the Internet website of the Centers for Medi-
8
care & Medicaid Services the summary included for 
9
such justification. 
10
‘‘(e) PENALTIES.— 
11
‘‘(1) FAILURE TO SUBMIT TIMELY JUSTIFICA-
12
TION.—If the Secretary determines that a manufac-
13
turer has failed to submit a justification as required 
14
under this section, including in accordance with the 
15
timing and form required, with respect to an appli-
16
cable drug, the Secretary shall apply a civil mone-
17
tary penalty in an amount of $10,000 for each day 
18
the manufacturer has failed to submit such justifica-
19
tion as so required. 
20
‘‘(2) FALSE INFORMATION.—Any manufacturer 
21
that submits a justification under this section that 
22
knowingly provides false information in such jus-
23
tification is subject to a civil monetary penalty in an 
24
01:38 Jul 27, 2021
H4418
10 
•HR 4418 IH
amount not to exceed $100,000 for each item of 
1
false information. 
2
‘‘(3) APPLICATION OF PROCEDURES.—The pro-
3
visions of section 1128A (other than subsections (a) 
4
and (b)) shall apply to a civil monetary penalty 
5
under this subsection in the same manner as such 
6
provisions apply to a penalty or proceeding under 
7
section 1128A(a). Civil monetary penalties imposed 
8
under this subsection are in addition to other pen-
9
alties as may be prescribed by law. 
10
‘‘(f) DEFINITIONS.—In this section: 
11
‘‘(1) APPLICABLE DRUG.— 
12
‘‘(A) IN GENERAL.—Subject to paragraph 
13
(2), the term ‘applicable drug’ means, with re-
14
spect to a lookback period described in para-
15
graph (2), a covered outpatient drug (as de-
16
fined in paragraph (2) of section 1927(k), with-
17
out application of paragraph (3) of such sec-
18
tion) that is covered under title XVIII and is 
19
not a low cost drug. 
20
‘‘(B) EXCLUSION OF LOW COST DRUGS.— 
21
For purposes of subparagraph (A)(iii), not later 
22
than January 1, 2023, the Secretary shall 
23
specify a threshold (such as a cost or spending 
24
threshold) for identifying (and shall identify) 
25
01:38 Jul 27, 2021
H4418
11 
•HR 4418 IH
low cost drugs to be excluded from the defini-
1
tion of the term ‘applicable drug’, such as a 
2
drug that has a wholesale acquisition cost of 
3
less than $10 per unit or less than $100 in av-
4
erage estimated expenditures under title XVIII 
5
per individual per year or per user of such drug 
6
per year. For purposes of this section, a drug 
7
shall not be considered specified as a low cost 
8
drug for a lookback period described in para-
9
graph (2) with respect to a year unless such 
10
drug is identified as being below the specified 
11
threshold for the entirety of the lookback pe-
12
riod. 
13
‘‘(2) MANUFACTURER.—The term ‘manufac-
14
turer’ has the meaning given that term in section 
15
1847A(c)(6)(A). 
16
‘‘(3) WHOLESALE
ACQUISITION
COST.—The 
17
term ‘wholesale acquisition cost’ has the meaning 
18
given that term in section 1847A(c)(6)(B).’’. 
19
Æ 
01:38 Jul 27, 2021
H4418
